Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379524 | 0.90 | CNR2 (0.64) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL3380681 | 0.90 | CNR2 (0.64) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL3378920 | 0.88 | CNR2 (0.64) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL13503318 | 0.85 | CNR2 (1.00) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL13503371 | 0.83 | CNR2 (0.79) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL13503320 | 0.82 | CNR2 (1.00) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL25420116 | 0.81 | CNR2 (0.59) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL13069566 | 0.81 | CNR2 (1.00) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL13069958 | 0.80 | CNR2 (0.80) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL541764 | 0.80 | CNR2 (1.00) | CNR2CYP2C9CYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP2C9 969/4885CYP3A4 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.